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Available online 16 August 2019Background:Upto30–40%ofEwingsarcoma(EwS)patientswithnon-metastaticdiseasedevelop local ormetasta-
tic relapsewithina timespanof 2–10years. This is inpart causedby the absence of prognostic biomarkers that can
identify high-risk patients and thus assign them to risk-adaptedmonitoring and treatment regimens. Since cancer
stemnesshasbeenassociatedwithtumourrelapseandpoorpatientoutcomes,weinvestigatedinthecurrentstudy
theprognostic potential of SOX2(sexdetermining regionYbox2)– amajor transcription factor involved indevel-
opment and stemness –whichwas previously described to contribute to the undifferentiated phenotype of EwS.
Methods: Two independent patient cohorts, one consisting of 189 retrospectively collected EwS tumours with
corresponding mRNA expression data (test-cohort) and the other consisting of 141 prospectively collected
formalin-fixed and paraffin-embedded resected tumours (validation-cohort), were employed to analyse SOX2
expression levels through DNA microarrays or immunohistochemistry, respectively, and to compare them
with clinical parameters and patient outcomes. Two methods were employed to test the validity of the results
at both the mRNA and protein levels.
Findings: Both cohorts showed that only a subset of EwS patients (16–20%) expressed high SOX2 mRNA or pro-
tein levels, which significantly correlated with poor overall survival. Multivariate analyses of our validation-
cohort revealed that high SOX2 expression represents a major risk-factor for poor survival (HR = 3·19; 95%CI
1·74–5·84; p b 0·01) that is independent from metastasis and other known clinical risk-factors at the time
of diagnosis. Univariate analyses demonstrated that SOX2-high expression was correlated with tumour relapse
(p = 0·002). The median first relapse was at 14·7 months (range: 3·5–180·7).
Interpretation: High SOX2 expression constitutes an independent prognostic biomarker for EwS patients with
poor outcomes. This may help to identify patients with localised disease who are at high risk for tumour relapse
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relapse.1. Introduction
Ewing sarcoma (EwS), the second most common bone and soft tis-
sue cancer in children and adolescents, potentially arises from
neuroectodermal or mesodermal mesenchymal stem cells [1]. In fact,
EwS tumours display a largely undifferentiated and ‘stemness’ pheno-
type, which is believed to contribute to its clinical aggressiveness [1].
Genetically, the hallmark of EwS is chromosomal translocations that
generate chimeric proteins through fusion of the EWSR1 (Ewing sarcoma
breakpoint region 1) gene to various members of the ETS (E26 transfor-
mation specific) family of transcription factors, in 85% FLI1 (Friend leuke-
mia virus integration 1) [2–4]. These EWSR1-ETS fusion oncoproteins act
as aberrant transcription factors that promote tumour initiation and
progression by massively rewiring the cellular transcriptome and
spliceosome [1].
Of EwS patients, 60–75% benefit from multimodal therapy [5,6].
Consequently, N30% of patients show a limited response to treatment,
which is often first noted based on assessment of their histological re-
sponse following neoadjuvant chemotherapy [7]. Since limited treat-
ment response may be associated with early relapse [8], upfront
identification of high-risk patients is essential to assigning them to ade-
quate treatment regimens. Despite several clinicopathological features
(such as tumour volume, histological response, tumour site and age at
diagnosis) have been associated with high-risk disease, the presence
of metastasis at diagnosis remains, thus far, the major factor for risk-
stratification in EwS patients [9]. However, for patients with localised
disease, risk prediction remains difficult, as no bona fide prognostic bio-
markers independent from metastasis are available [1,10].
A previous report has indicated that stemness in EwS may be me-
diated via EWSR1-FLI-induced expression of SOX2 (sex determining re-
gion Y box 2) [11] – a well-known stemness gene overexpressed in
many cancers [12]. We therefore explored, in the current study, the
expression pattern of SOX2 in two independent EwS cohorts and in-
vestigated whether SOX2 may serve as a biomarker for outcome pre-
diction in EwS.
We show that SOX2 is expressed only in ~16–20% of EwS tumours
and is associated with very poor patient outcome independent of me-
tastasis at time of diagnosis. Moreover, high expression of SOX2 is sig-
nificantly correlated with local and/or metastatic tumour relapse. Our
findings suggest that detection of high SOX2 expression through immu-
nohistochemistry or RNA-based techniques may constitute a broadly
available biomarker for risk-stratification even for patients with local-
ised disease.
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2.1. Study populations
For this study, a retrospective test-cohort and a prospective
validation-cohort were analysed. Patient characteristics of both cohorts
are listed in Table 1.
The study population of the test-cohort consisted of 189 EwS pa-
tients whose molecularly confirmed and retrospectively collected pri-
mary tumours were profiled at the mRNA level by gene expression
microarrays in previous studies [13–16]. To assemble this mRNA-
cohort, microarray data generated on Affymetrix HG-U133Plus2.0,
Affymetrix HuEx-1.0-st or Amersham/GE Healthcare CodeLink micro-
arrays of the 189 EwS tumours (Gene Expression Omnibus (GEO) ac-
cession codes: GSE63157 [13], GSE12102 [14], GSE17618 [15],
GSE34620 [16], and unpublished data) provided with clinical annota-
tions were normalised separately as previously described [17]. Based
on specific gene expressions, we predicted for each sample the tumour
purity via the ESTIMATE algorithm [18], which revealed that all sam-
ples had a consensus purity estimation of N60%, corresponding to The
Cancer Genome Atlas (TCGA) standard tissue sample requirements
(http://cancergenome.nih.gov/cancersselected/biospeccriteria). Only
genes that were represented on all microarray platforms were kept
for further analysis. Batch effects were removed using the ComBat al-
gorithm [19]. The removal of batch effects was demonstrated by t-
SNE analysis of gene expression data before and after the batch correc-
tion (appendix fig. 1). This yielded a dataset comprising 189 EwS sam-
ples and 13,253 genes. Data processing was done in the statistical
language R.
The validation-cohort was composed of 141 EwS patients treated
with first-line therapy according to the successive phase III EwS proto-
cols of European Intergroup Cooperative Ewing's Sarcoma Study
(EICESS) 92 (1992 to 1998), and EURO-EWING 99 (1999 to 2009) run
by the German Society for Paediatric Oncology and HaematologyTable 1
Patients characteristics (n = 189;141).
Variable Test-cohort (mRNA) n (%) Validation-cohort (TMA) n (%)
Sex





b15 years 112 (59·3) 70 (49·7)
≥15 years 77 (40·7) 71 (50·3)
Metastasis at diagnosis





Axial NA 86 (61·9)
Non-axial NA 53 (38·1)
(missing: 2)
Tumour volume
b200 ml NA 76 (55·9)
b200 ml NA 60 (44·1)
(missing: 5)
Histological responseb
Good NA 67 (79·8)
Poor NA 17 (20·2)
(missing: 57)
Status
Alive 113 (59·8) 84 (59·6)
Dead 76 (40·2) 57 (40·4)
SOX2 expression
High 38 (20·1) 22 (15·6)
Low 151 (79·9) 119 (84·4)
a All extremity localization are non-axial.
b NA = not available.(GPOH). These studies were registered under ClinicalTrials.gov and ap-
proved by the appropriate ethics committees. The corresponding pa-
tient tumours were prospectively collected and tissue microarrays
(TMAs) were constructed as detailed below. This study population in-
cluded 87 males and 54 females.2.2. TMA establishment and immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded (FFPE) EwS samples were re-
trieved from the archives of the Institute of Pathology of the LMU Mu-
nich (Germany) and the Gerhard-Domagk-Institute for Pathology of
the University of Münster (Germany) with approval from the corre-
sponding institutional review boards. All EwS samples were collected
at diagnosis and reviewed by a reference pathologist, and diagnoses
were confirmed by the detection of pathognomonic EWSR1-ETS fusion
oncogenes by qRT-PCR or the detection of an EWSR1 break-apart by
fluorescence-in-situ-hybridisation (FISH). TMAs were constructed as
previously described [17]. Each EwS case was represented by at least
two cores (each 1 mm in diameter).
For IHC, 4 μm sections were cut, and antigen retrieval was per-
formed using microwave treatment. Slides were incubated with a pri-
mary monoclonal rabbit anti-SOX2-antibody (1:100 dilution, D6D9
XP Cell Signaling) for 60 min. Then, the slides were incubated with a
secondary anti-rabbit IgG antibody (ImmPress Reagent Kit;
peroxidase-conjugated) followed by target detection using AECplus
chromogen for 10 min (Dako, K3461). The specificity of the anti-
SOX2-antibody used was confirmed in xenografts of the EwS cell line
POE in NOD/Scid/gamma (NSG) mice, in which SOX2 expression was
silenced by a doxycycline (dox-)inducible shRNA against the 3’UTR of
SOX2 (appendix fig. 4B). For quantification of SOX2 immunoreactivity,
the average percentage of SOX2-positive nuclei was evaluated by a
data-blinded pathologist who examined at least five high-power fields
per case. Examples of nuclear SOX2 immunoreactivity are given in
Fig. 1D.2.3. Statistical analyses
In the mRNA-cohort, the optimal cut-off for stratifying patients by
SOX2 expression levels was identified by in-house software (GenEx),
which tested all possible cut-offs between the 20th and 80th expres-
sion percentiles for the largest difference in area under the curves in the
Kaplan-Meier analyses. This analysis identified the 80th percentile of
SOX2 expression as the optimal cut-off for stratification of the mRNA-
cohort in SOX2-high and -low. Statistical analyses were carried out
with SPSS 19 (IBMCorporation, Armonk, NY) and SAS 9.2 (SAS Institute,
Cary, NC) as described [20]. Event-free survival (EFS) and overall sur-
vival (OS) were estimated using the Kaplan-Meier method. OS time
was defined as the interval between the date of diagnosis and the date
of the patient'sfinal follow-up or death. Group comparisonswere calcu-
lated using the log-rank test. Multivariate analyses were carried out by
applying the Cox proportional hazard method. Differences in propor-
tions between groups were evaluated using chi-square or Fisher's
exact tests. The significance level was set at p b 0·05 for two-sided test-
ing. No alpha correctionswere carried out formultiple testing. Outcome
was analysed on an exploratory basis.2.4. Role of the funding source
The funders of the study had no role in the study design, data
collection, data analysis, data interpretation, or writing of the report.
Both corresponding authors had full access to all the data in the
study and had final responsibility for the decision to submit for
publication.
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3.1. SOX2 is expressed in a subset of EwS patients and is correlated with OS
SOX2 is awell-known transcription factor involved in stemness dur-
ing normal development and cancer [12]. In 2010, Riggi et al. proposed
that EWSR1-FLI1 confers stemness features to EwS cells via up-
regulation of SOX2 [11]. We therefore reasoned that SOX2 expression
levels might be connected to patient outcome.
To test this hypothesis, a test-cohort obtained from a large EwS gene
expression dataset comprising 189 samples, for which matched clinical
datawere available (Table 1), was employed to evaluatemRNA levels of
SOX2. In contrast to previous suggestions that SOX2 overexpression
might constitute a general feature of EwS [11], we found, using amicro-
array analysis, that SOX2 mRNA was not or was only minimally
expressed in 79·9% (151/189) of tumours. Indeed, only 20·1% (38/
189) of the samples exhibited moderate to strong SOX2 expression
levels (Fig. 1A). Stratifying our mRNA-cohort by a cut-off of the 80thFig. 1. SOX2 is expressed in a subset of EwS patients and correlates with event-free survival (
primary EwS cases. (B). Kaplan-Meier analysis of OS in 189 EwS patients stratified by thei
expression levels in an independent cohort of 141 EwS patients in a TMA by IHC. (D). Re
percentages of nuclear SOX2 immunoreactivity. Scale bars = 50 μM (40×) and 200 μM (10×
expression level (cut-off N10% positive nuclei). (F). Kaplan-Meier analysis of OS in 141 EwS papercentile of SOX2 expression in SOX2-low or -high cases, we noted
that patients with high intratumoural SOX2 expression had worse OS
than patients with low SOX2 expression (p b 0·0001) (Fig. 1B).
To validate this finding at the protein level, we stained an
independent validation TMA-cohort comprising 141 EwS cases with
an anti-SOX2-antibody with proven specificity for EwS (appendix
fig. 4B). Patient characteristics are reported in Table 1. Scoring of the
percentage of nuclear SOX2 positive cells confirmed that the majority
of EwS cases (84·4%; 119/141) showed ≤10% positive nuclei (classified
as SOX2-low)while only a small subset of patients (15·6%; 22/141) had
N10% positive nuclei (classified as SOX2-high) (Fig. 1C,D). Strikingly, ap-
plying the cut-off of N10% SOX2 positive nuclei fully confirmed the
strong association of SOX2 expression with poor event-free survival
(EFS) (p = 0·0008) and OS of EwS patients (p = 0·0004) (Figs. 1E,F).
In both the mRNA-test and TMA-validation cohorts, EwS samples
were reviewed by a reference pathologist and diagnosis was
confirmed either by the detection of pathognomonic EWSR1-ETS fusion
oncogenes by qRT-PCR or the detection of an EWSR1 break-apart byEFS) and overall survival (OS). (A). Microarray analysis of SOX2mRNA expression in 189
r SOX2 mRNA expression level (cut-off 80th percentile). (C). Analysis of SOX2 protein
presentative images for SOX2 IHC (nuclear staining) in EwS patients with different
). (E). Kaplan-Meier analysis of EFS in 141 EwS patients stratified by their SOX2 protein
tients stratified by their SOX2 protein expression level (cut-off N10% positive nuclei).
Table 2
Multivariate analysis in all patients (n = 141).
Variable HR (95%CI) p
Risk group
M0 (no met; n = 87) Ra b0·01
M1 (lung met; n = 24) 1·76 (0·85–3·62) 0·13
M2 (other +/− lung met; n = 30) 4·86 (2·65–8·91) b0·01
SOX2
High (N10%) 3·19 (1·74–5·84) b0·01
Age
≥15 years 1·34 (0·79–2·27) 0·28
Site
Axial 1·64 (0·90–2·96) 0·11
a R = Reference.
Table 3
Multivariate analysis in patients with localised disease (n = 87).
Variable HR (95%CI) p
SOX2
High (N10%) 3·22 (1·36–7·65) b0·01
Age
≥15 years 2·43 (1·05–5·61) 0·04
Site
Axial 1·66 (0·70–3·92) 0·25
160 G. Sannino et al. / EBioMedicine 47 (2019) 156–162fluorescence-in-situ-hybridisation (FISH). To investigate whether the
fusion type (EWSR1-FLI1 type 1 and type 2 and EWSR1-ERG) affects
SOX2 expression in EwS, we analysed data obtained from 18 EwS cell
lines with different fusion types. These data demonstrated that there
is no significant difference in SOX2 expression between EwS cell lines
with different fusion types (appendix fig. 2).
Collectively, these results demonstrated, for the first time, that high
SOX2 expression is not a common feature of EwS, but its highmRNAand
protein levels may serve as a biomarker for outcome prediction.
3.2. High SOX2 expression is a major risk-factor for tumour associated-
death independent from metastasis at time of diagnosis in EwS
To identify factors that may influence patient prognosis, we per-
formed a multivariate analysis in our validation TMA-cohort, as here,
additional clinicopathological information beyond OS was available. In-
terestingly, the multivariate analysis revealed that the major risk-
factors were metastatic disease at time of diagnosis at the M2 stage
and SOX2-high expression with hazard ratios (HRs) of 4·86 and 3·19
(both p b 0·01), respectively. Instead, M0 (HR = R; p b 0·01), M1
(n=24; HR= 1·76; p=0·13), age (≥15 years; HR=1·34; p=0·28)
and primary axial tumour site (HR = 1·64; p= 0·11) did not show a
significant impact on survival (n=141; Table 2).
To exclude an interdependency of metastasis at time of diagnosis
and SOX2 expression status, we repeated the multivariate analysis con-
sidering only patients with localised disease (M0, n= 87). In this anal-
ysis, SOX2-high expression (HR = 3·22; p b 0·01) represented the
main risk-factor for survival, followed by age (≥15 years; HR = 2·43;
p = 0·04), whereas primary axial tumour site (HR = 1·66; P = 0·25)
showed only a tendency to affect survival (Table 3; n = 87). In agree-
ment with these findings, in both validation- and test-cohorts, univari-
ate analysis did not show a correlation between SOX2-high and
metastasis at time of diagnosis (Table 4, n = 141, p = 0·8; and
Table 5, n = 76, p 0·5). Taken together, these findings demonstrate
that SOX2-high expression constitutes an independent risk-factor for
survival of EwS patients, even in patients with localised disease.
3.3. High SOX2 expression is significantly correlated with tumour relapse
Next, we investigated whether the correlation between SOX2-high
expression and OS is associatedwith histological response, high tumour
volume (≥200 ml), and relapse, which are risk-factors for worse out-
comes [10,21–23].
In our TMA-cohort, data on histological response, tumour volume,
and tumour relapsewere available for 84, 136 and 141 patients, respec-
tively (Table 4). Our data did not show an association between high
SOX2 expression and histological response (Table 4). However, we ob-
served a tendency for an association between SOX2-high and tumour
volume. In fact, 58·3% of patients with high SOX2 expression had a tu-
mour volume ≥ 200 ml compared to 41·7% patients with low SOX2 ex-
pression (p= 0·23) (Table 4). Since the association of SOX2 and higher
tumour volume suggested a role for SOX2 in EwS growth,we performed
functional in vitro and in vivo experiments using an established EwS cell
line model (POE) for which we generated a derivate with a doxycycline
(dox-)inducible shRNA against SOX2. The results showed that the
knockdown of SOX2 in POE cells led to strong reduction in cell prolifer-
ation, clonogenic growth and anchorage-independent growth com-
pared to cells that expressed a non-targeting control shRNA (appendix
fig. 4). Consistently, dox-induced silencing of SOX2 in POE cells
xenografted in immunocompromised NSG mice significantly reduced
tumour growth (appendix fig. 4).
In addition, we noted a striking correlation between SOX2-high ex-
pression and tumour relapse (p = 0·002) (Table 4), comprising in
86% of cases metastatic relapse (n = 39) or combined metastatic
and local relapse (n= 17), and in 14% of cases exclusively local relapse
(n = 9). While only 40·3% of patients with SOX2-low expression hadrelapses, recurrence occurred in 77·3% of patients with SOX2-high ex-
pression (Table 4), which may explain the poor outcome that was ob-
served for these patients. Indeed, immunohistological assessment of
12 available pairs of primary EwS and relapse samples showed that
while SOX2-high expression was only observed in one case at the
time of diagnosis four cases exhibited SOX2-high expression at relapse
(average percentage of SOX2 expression: 2·75 in primary EwS vs.
15·5 in relapse tumours, p = 0·219; Wilcoxon matched-pairs signed
rank test). In agreement with these observations, gene set enrichment
analysis (GSEA) in our mRNA cohort showed that genes co-expressed
with SOX2 in primary EwS tumours are involved in stemness, prolifera-
tion, dedifferentiation, and cancer relapse (appendix fig. 5A, appendix
table 1).
Collectively, these results suggest that SOX2-high expression may
confer worse outcomes for EwS patients by contributing to tumour
growth and relapse.
4. Discussion
Up to 30–40% of EwS patients with non-metastatic disease develop
local ormetastatic relapsewithin a time span of 2–10 years [24]. Clinical
prognostic markers, such as primary dissemination, tumour site, size,
age, and histological response to chemotherapy, are established risk-
factors used for therapeutic stratification [24]. However, especially for
patients with localised disease and otherwise no apparent risk-factors,
risk prediction is challenging [25]. Although there is broad consensus
that clinical managementwill benefit fromprognostic or predictive bio-
markers that can guide therapeutic decisions, there are currently no
bona fide or broadly available biomarkers that may help predict tumour
relapse and outcome among patients with EwS [1,10]. A recent retro-
spective study on a single cohort of 63 EwS patients with localised dis-
ease suggested that detection of a higher tumour-mutational-burden
(TMB) in EwSmay help to identify patients at risk for relapse among pa-
tients with localised disease [26]. However, TMB detection requires so-
phisticated sequencing technologies that may not be technically
applicable in all EwS cases.
In this study, we reported, for the first time, that high mRNA or pro-
tein expression of SOX2,which can bedeterminedwith routine technol-
ogies such as immunohistochemical stains, is a stratification risk-factor
for ~16–20% of EwS patients with poor outcomes. Notably, multivariate
analyses that included either all or only patients with localised disease
have demonstrated that SOX2-high expression represents an
Table 4









No Yes p Good Poor p b200 ml ≥200 ml p No Yes p
SOX2
Low 74 (62·2%) 45 (37·8%) 0·8 57 (79·2%) 15 (20·8%) 1·0 67 (58·3%) 48 (41·7%) 0·23 71 (59·7%) 48 (40·3%) 0·002
High 13 (59·1%) 9 (40·9%) 10 (83·3%) 2 (16·7%) 9 (42·9%) 12 (57·1%) 5 (22·7%) 17 (77·3%)
161G. Sannino et al. / EBioMedicine 47 (2019) 156–162independent and strong risk-factor for EwS patients. In fact, SOX2-high
expression has beenmore frequently observed in relapsed tumours, and
SOX2-high expression in primary tumours is significantly associated
with early relapse in patients with localised disease and no other appar-
ent clinical risk-factors. In linewith our findings in EwS, high expression
or amplification of SOX2 has been reported to correlate with poor sur-
vival in breast, colorectal, esophageal, laryngeal, endometrial, and ovar-
ian carcinomas [12]. Like in EwS, SOX2 is highly expressed in a subset of
patients with lung adenocarcinomas and was found to be an indepen-
dent predictor of poor survival [27].
Previous reports have suggested that SOX2 may constitute a direct
EWSR1-FLI1 target gene [11,28]. Surprisingly, we found that the vast
majority of molecularly confirmed EwS cases do not express SOX2 nei-
ther at themRNAnor the protein level, suggesting that themode of reg-
ulation and the functional role of SOX2 may be more complex than
previously thought. Recently, Boulay et al. identified a polymorphic
EWSR1-FLI1-bound enhancer-like GGAA-microsatellite near SOX2, and
demonstrated that epigenetic silencing of this DNA sequence strongly
reduced SOX2 expression in EwS cells [28]. In fact, EWSR1-FLI1 encodes
an aberrant transcription factor, which induces many of its target genes
by binding to enhancer-like GGAA-microsatellites, whose activity in-
creases with the number of consecutive GGAA-repeats [1,29].
Since the number of GGAA-repeats at such EWSR1-FLI1-bound
GGAA-microsatellites is highly variable across individuals [30,31], it is
tempting to speculate that the number of GGAA-repeats at the
SOX2-associated GGAA-microsatellite may contribute to the strong
heterogeneity of SOX2 expression in EwS patients.
In our TMA-cohort, SOX2-high expression showed a correlationwith
tumour relapse (p=0·002), which likely explains the poor outcome of
these patients. In support of our findings, it has been shown in sinonasal
carcinomas that patients with SOX2 amplification have a significantly
higher rate of tumour recurrence than thosewithout SOX2 amplification
[32]. However, in our TMA-cohort 38·7% of patients with SOX2-low ex-
pression showed relapses, suggesting that in this subset of patients, a
different driver might mediate tumour relapse.
Although the correlation between high SOX2 expression and tumour
volumewas not significant in our TMA-cohort, in line with previous re-
ports regarding EwS [11,33], our in vitro and in vivo results confirmed a
functional role of SOX2 in EwS cell proliferation and tumour growth
suggesting that a larger cohort might enable validation of this correla-
tion in EwS patients. In agreement with this, our GSEA in primary EwS
indicated that SOX2-high tumours are enriched for gene signatures in-
volved in dedifferentiation, proliferation, and stemness, whichmay pro-
mote tumour relapse. Interestingly, GSEA also revealed that SOX2 co-
expressed genes overlap with genes involved in relapse of malignant
melanoma – a tumour of neuroectodermal origin [34] that has alsoTable 5




Low 45 (71·4%) 18 (28·6%) 0·5
High 8 (61·5%) 5 (38·5%)been proposed for EwS [1]. In support of these data, GSEA of differen-
tially expressed genes upon SOX2 knockdown in three SOX2-high EwS
cell lines demonstrated a significant upregulation of gene signatures in-
volved in differentiation-related processes, such as neurite outgrowth,
integrin cell surface interaction, and components of the basementmem-
brane (appendix fig. 5B, appendix table 2).
Despite the exploratory nature of this study, SOX2-high expression
may constitute the first promising biomarker for outcome prediction
and stratification of high-risk EwS patients with localised disease,
which is readily available due to standardised assessments by qRT-
PCR and/or IHC. Early identification of such high-risk patients may en-
able clinicians to apply a closer monitoring and eventually intervene
earlier in cases of incipient relapse. In addition, translational and clin-
ical studies aimed at discovering specific therapeutic approaches for
this high-risk sub-group of EwS patients could be initiated. Therefore,
we recommend validation of these observations in additional prospec-
tive studies and experimental elucidation of the precise molecular role
of SOX2 in EwS. For prospective studies, we recommend to evaluate
the SOX2 expression status by IHC following our staining protocol
during routine pathology work-up on diagnostic specimens and to
apply the same cut-off as described here (N10% positive nuclei of tu-
mour cells) for classifying samples in SOX2-high and -low, respec-
tively. Since immunohistochemical stains for SOX2 are relatively
easy to establish, inexpensive, and straight-forward to evaluate from
a pathologist's perspective, we anticipate that this biomarker can be
widely used in the clinics. For these reasons, SOX2 will be assessed
prospectively in the new iEuroEwing trial led by the Cooperative
Ewing Sarcoma Study (CESS) group of the German Society for
Paediatric Oncology and Haematology (GPOH) (U. Dirksen personal
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